Introduction
Incidence of breast cancer in the seven major markets will total 455,000 in 2008, while 115,000 women will die from the disease. Despite advances in treatment over the past decade, significant unmet needs remain. This level of demand and the large patient potential make breast cancer a relatively attractive indication for drug developers.
Scope
Examination of the breast cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates
Seven major pharmaceutical sales forecasts for Phase III pipeline products through to 2017 with product-specific assumptions
Segmentation and analysis of the current breast cancer pipeline by developmental phase, drug class, company and indication
Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
Report Highlights
There are 121 drugs in clinical development for breast cancer. Molecular targeted therapies are the predominant therapy class in the breast cancer pipeline, accounting for 50% of the pipeline. Cytotoxic therapies account for 25% of the pipeline, while therapeutic vaccines account for 13%, and endocrine therapies account for just 6% of the pipeline.
Seven drugs are in late-phase development for breast cancer, of which four are molecular targeted therapies. Collectively, the late-phase pipeline candidates are forecast to achieve $2,230m in sales in 2017 in the seven major pharmaceutical markets. The late-phase molecular targeted therapies account for the majority of this with sales of $2,142m.
The majority (82%) of clinical trials of drugs in late-phase development for breast cancer are in the metastatic setting. This reflects the higher level of unmet need, lower bar to market entry and shorter trial completion time as compared with the adjuvant or neoadjuvant treatment setting.
Reasons to Purchase
Identify key drugs and companies involved in the breast cancer pipeline based on sales forecasts to 2017 and Datamonitor drug assessment
Understand what the key hurdles to commercial and clinical success are for drugs in late-phase development for breast cancer
Characterize unmet need and poorly served patient subsets within breast cancer and assess the potential for pipeline products to provide satisfaction
'Pipeline Insight: Breast Cancer - Recent approvals increase pressure on pipeline candidates' is a report from Datamonitor, a leading provider of online data, analytic and forecasting platforms for key vertical sectors.